<DOC>
	<DOCNO>NCT02141074</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate safety efficacy nonacog beta pegol ( N9-GP ) previously untreated patient Haemophilia B .</brief_summary>
	<brief_title>Safety Efficacy Nonacog Beta Pegol ( N9-GP ) Previously Untreated Patients With Haemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male , age 6 year time signing informed consent Patients diagnosis haemophilia B ( FIX ( coagulation factor IX ) activity level equal 2 % ) base medical record central laboratory result Previously untreated exposed FIX containing product less equal 3 exposure day ( 5 previous exposure blood component acceptable ) Any history FIX inhibitor ( define medical record ) Known suspect hypersensitivity trial product relate product Previous participation trial . Participation define first dose administer trial product Receipt investigational medicinal product within 30 day screen Congenital acquire coagulation disorder haemophilia B Any chronic disorder severe disease , opinion Investigator , might jeopardise patient 's safety compliance protocol Patient 's parent ( ) /LAR ( ) ( legally acceptable representative ) mental incapacity , unwillingness cooperate , language barrier preclude adequate understanding cooperation</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>